Minerva Neurosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

04.11.19	Minerva Neurosciences Reports Third Quarter 2019 Financial Results and Business Updates (GlobeNewswire)
28.10.19	Minerva Neurosciences to Report Third Quarter 2019 Financial Results and Business Updates on November 4, 2019 (GlobeNewswire)
02.10.19	Today's Top 5 Losers In Healthcare Sector (NERV, NLNK, CYCN…) (RTTNews)
01.10.19	Minerva Neurosciences Announces Update for Three Clinical Trials (GlobeNewswire)
26.09.19	Minerva Neurosciences to Host Conference Call and Live Webcast on Tuesday, October 1 at 8:30 AM ET (GlobeNewswire)
24.09.19	Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone (GlobeNewswire)
05.08.19	Minerva Neurosciences Reports Second Quarter 2019 Financial Results and Business Updates (GlobeNewswire)
29.07.19	Minerva Neurosciences to Report Second Quarter 2019 Financial Results and Business Updates on August 5, 2019 (GlobeNewswire)
25.06.19	5 Top Gainers In Healthcare Sector (IMUX, KRYS, NERV...) (RTTNews)
24.06.19	Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia (GlobeNewswire)
23.06.19	Minerva Neurosciences to Host Live Conference Call and Webcast With Key Opinion Leaders to Discuss Successful Insomnia Trial With Seltorexant (GlobeNewswire)
16.06.19	Will These 5 Biotechs Hit The Bulls-Eye Or Miss The Mark? (RTTNews)
12.06.19	Minerva Neurosciences to Present at JMP Securities Life Sciences Conference (GlobeNewswire)
29.05.19	Minerva Neurosciences to Present at Jefferies 2019 Global Healthcare Conference on June 4, 2019 (GlobeNewswire)
13.05.19	Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs (GlobeNewswire)
06.05.19	Minerva Neurosciences Reports First Quarter 2019 Financial Results and Business Updates (GlobeNewswire)
16.04.19	AXSM Has Had An Awesome Run. What Awaits These 13 Biotech Stocks In Q2, 2019? (RTTNews)
18.03.19	Minerva Neurosciences to Host Webcast Event on Schizophrenia (GlobeNewswire)
12.03.19	Minerva Neurosciences Reports Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates (GlobeNewswire)
05.03.19	Minerva Neurosciences to Report Fiscal 2018 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2019 (GlobeNewswire)
21.11.18	Minerva Neurosciences to Present at Evercore ISI HealthCONx Conference on November 28, 2018 (GlobeNewswire)
19.11.18	Minerva Neurosciences Announces Results of Dose Escalation Study Evaluating Roluperidone (MIN-101) Administered at Supra-Therapeutic Doses in Healthy Volunteers (GlobeNewswire)
15.11.18	Minerva Neurosciences to Host Roluperidone Update and Key Opinion Leader Discussion of Negative Symptoms in CNS/Psychiatric Diseases on November 20, 2018 (GlobeNewswire)
05.11.18	Minerva Neurosciences Reports Third Quarter 2018 Financial Results and Business Updates (GlobeNewswire)
29.10.18	Minerva Neurosciences to Report Third Quarter 2018 Financial Results and Business Updates on November 5, 2018 (GlobeNewswire)
22.08.18	Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor (BDNF) (GlobeNewswire)
02.08.18	Minerva Neurosciences Reports Second Quarter 2018 Financial Results and Business Updates (GlobeNewswire)
26.07.18	Minerva Neurosciences to Report Second Quarter 2018 Financial Results and Business Updates on August 2, 2018 (GlobeNewswire)
25.07.18	Minerva Neurosciences Names Devin Smith Senior Vice President, General Counsel (GlobeNewswire)
17.07.18	Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors (GlobeNewswire)
30.05.18	Minerva Neurosciences to Present at Jefferies 2018 Global Healthcare Conference on June 6, 2018 (GlobeNewswire)
18.05.18	EIGR Soars On Progeria Deal, BOLD Investors Emboldened, BDSI's Cash Strengthens (RTTNews)
17.05.18	MÄRKTE USA/Wall Street kann leichte Aufschläge nicht halten (Dow Jones)
17.05.18	Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symp... (GlobeNewswire)
03.05.18	Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates (GlobeNewswire)
26.04.18	Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018 (GlobeNewswire)
09.04.18	Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder (GlobeNewswire)
15.03.18	Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22 (GlobeNewswire)
12.03.18	Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates (GlobeNewswire)
05.03.18	Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018 (GlobeNewswire)
08.02.18	TBPH Inks $1Bln Deal, SGMO Hits Yearly High, ANAB Is Back Again (RTTNews)
05.02.18	Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director (GlobeNewswire)
21.12.17	Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With... (GlobeNewswire)
19.12.17	Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia (GlobeNewswire)
11.12.17	Minerva Neurosciences Names Richard Russell President (GlobeNewswire)
11.12.17	Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors (GlobeNewswire)
06.12.17	Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder (GlobeNewswire)
30.11.17	PTI Faces Busy December, CYTK Displays Fortitude, LENS Losing Sharpness? (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu Minerva Neurosciences Inc

Aktien Top/Flop

Meistgelesene Nachrichten